PFIZERNSEPfizer Limited· PharmaceuticalsHighNeutral
Announced Tue, 12 May · 19:52 IST

Pfizer Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Exceptional ItemResults View source PDF

PFIZER · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.5%1-day move
₹4725.00
prior close
₹4651.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.8+1.0+1.2+0.3-1.5+2.7+2.9+1.2-1.0-1.4-6.3-4.3+0.2
Up moveDown movePending
AI summary

Pfizer Limited reported revenue from operations of ₹2,519.65 crore for FY2026, up 10.4% from ₹2,281.35 crore in the previous year. However, net profit declined 5.9% to ₹722.43 crore from ₹767.60 crore, impacted by exceptional items of ₹49.16 crore (personnel separation costs of ₹41.73 crore due to Cipla distribution agreement and ₹7.43 crore for new labour code provisions). EPS stood at ₹157.92 versus ₹167.79 in FY2025. The company declared an unmodified audit opinion and recommended a final dividend of ₹75 per share (750%). Operating cash flow remained strong at ₹967.57 crore.

Likely market impact

Revenue growth was moderate at 10.4%, but profit declined due to one-time restructuring charges. The clean audit opinion and strong cash flow are positives for shareholders. The ₹75 dividend signals confidence despite lower profitability.